Villigen, Switzerland-based ASTRA Therapeutics raised €8.3 million in a Seed funding round. MIG Capital AG led the investment, with Digitalis Ventures co-leading. This funding supports the company's work on precision parasiticides for animal health.
Advancing Animal Health Solutions
Founded in 2022, ASTRA Therapeutics develops novel parasitic agents. These drugs, known as Parabulins, control parasites by inhibiting cell division. The company's proprietary ParaX drug development platform generates species-specific drug leads. This approach aims to spare host animals while effectively targeting pathogens.
The global parasiticide market faces increasing drug resistance. ASTRA Therapeutics addresses this critical need with its innovative pipeline. Their candidates target common parasites like coccidia in farm animals and heartworm in dogs and cats. Companies like Zoetis and Elanco also operate in this expanding veterinary market.
This investment marks MIG Capital's first in Switzerland.
